Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Anant Parekh awarded prestigious Batsheva de Rothschild prize

Awards and Appointments General

Professor Anant Parekh (Department of Physiology, Anatomy & Genetics) has been awarded a Batsheva Prize from the Rothschild Foundation at the Israel Academy of Sciences and Humanities.

Anant Parekh has been awarded a Batsheva Prize from the Rothschild Foundation at the Israel Academy of Sciences and Humanities.  As part of the award, he will visit various Israeli Universities and Research Centres to deliver a lecture entitled: Store-operated calcium channels: gating, regulation and novel target for airway disease.

Anant is Professor of Cell Physiology, Director of the Centre of Integrative Physiology and a Fellow of Merton College. He has pioneered research on store-operated calcium channels, discovered how these proteins generate and signal through local Ca2+ microdomains and established a central role for the channels in the development of allergies and asthma.

Read more (Department of Physiology, Anatomy & Genetics website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Three ways virtual reality could transform mental health treatment

General Research

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.